Robert L. Rosiello is EVP & Corp Dev & Strategy at Valeant Pharmaceuticals International, Inc. (VRX). They have made 2 open-market trades across 1 company since 2015, most recently 2016-12-05.
CIK 0001645041
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $5.0M since 2015, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| VRX | 517,683 | $12.1M |
Shares reported on the most recent Form 4, priced at the 2016-12-07 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.